Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: Meta-Analyses of randomized trials

Journal of Hypertension

Volumn 34, Issue 10, 2016, Pages 1921-1932

  Thomopoulos, Costas ^a   Parati, Gianfranco ^b   Zanchetti, Alberto ^b,c  

^a HELENA VENIZELOU HOSPITAL   (Greece)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Adverse events; Antihypertensive drugs; Bloodpressure lowering trials; Cardiovascular event reduction; Hypertension; Meta Analysis; Randomized controlled trials; Treatment discontinuations

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; CALCIUM CHANNEL BLOCKING AGENT;

ADVERSE DRUG REACTION; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMBINATION DRUG THERAPY; DIASTOLIC BLOOD PRESSURE; DRUG WITHDRAWAL; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CORONARY DISEASE; STROKE; TREATMENT WITHDRAWAL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CORONARY DISEASE; DIURETICS; HEART FAILURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; WITHHOLDING TREATMENT;

EID: 84979708509     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001052     Document Type: Review

References (79)

1. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension 4. Effects of various classes of antihypertensive drugs. Overview and meta-Analyses. J Hypertens 2015; 33:195-211.
2. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension 5. Head-To-head comparisons of various classes of antihypertensive drugs. Overview and meta-Analyses. J Hypertens 2015; 33:1321-1341.
3. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 8. Outcome reductions versus discontinuations because of adverse drug events-meta-Analyses of randomized trials. J Hypertens 2016; 34:1451-1463.
4. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, metaanalyses and meta-regression analyses of randomized trials. J Hypertens 2014; 32:2285-2295.
5. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 7. Effects of more versus less intensive blood pressure lowering and different achieved blood pressure levels-updated overview and meta-Analyses of randomized trials. J Hypertens 2016; 34:613-622.
6. Management Committee. The Australian therapeutic trial in mild hypertension. Lancet 1980; 315:1261-1267.
7. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898.
8. Medical Research Council Working Party. MRC trial on treatment of mild hypertension: principal results. Br Med J 1985; 291:97-104.
9. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304:405-412.
10. Helgeland A. Treatment of mild hypertension: A five year controlled drug trial. The Oslo study. Am J Med 1980; 69:725-732.
11. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
12. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293:1145-1151.
13. Eriksson S, Olofsson B-O, Wester P-O, For the TEST (Tenormin after Stroke and TIA) Study Group. Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995; 5:21-25.
14. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-Acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomised controlled trial. Lancet 2004; 364:849-857.
15. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 2004; 292:2217-2225.
16. Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15:1042-1049.
17. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
18. Dens JA, Desmet WJ, Coussement P, De Scheerder IK, Kostopoulos K, Kerdsinchai P, et al. Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: The NICOLE study. Heart 2003; 89:887-892.
19. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with nondiabetic chronic renal disease (REIN-2): multicentre, randomized controlled trial. Lancet 2005; 365:939-946.
20. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939-945.
21. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al., Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951.
22. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Ménard J, DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: Randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328:495.
23. DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008; 31:1007-1014.
24. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group. The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
26. The PEACE Trial Investigators.Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-2068.
27. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomised placebo-controlled trial. Lancet 2008; 372:1385-1393.
28. The GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360:1606-1617.
29. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359:2456-2467.
30. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
31. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Eng J Med 2010; 362:1477-1490.
32. Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, Makino H, For the ORIENT Study Investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study. Diabetologia 2011; 54:2978-2986.
33. Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225-1237.
34. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
35. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al., ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907-917.
36. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886.
37. Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet 2008; 372:1174-1183.
38. Barraclough M, Bainton D, Cochrane AL. Control of moderately raised blood pressure. Report of a co-operative randomized controlled trial. BMJ 1973; 3:434-436.
39. Carter BA. Hypotensive therapy in stroke survivors. Lancet 1970; 295:485-489.
40. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA 1974; 229:409-418.
41. Sprackling ME, Mitchell JR, Short AH, Watt G. Blood pressure reduction in elderly: A randomised controlled trial of methyldopa. BMJ 1981; 283:1151-1153.
42. Smith WM. Treatment of mild hypertension: Results of a ten-year intervention trial. Circ Res 1977; 40:98-105.
43. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 90 through 114mm Hg. JAMA 1970; 213:1143-1152.
44. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: A randomized controlled trial. J Hypertens 2011; 29:1649-1659.
45. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5:561-572.
46. The IPPPSH Collaborative Groups. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3:379-392.
47. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-Term therapy. JAMA 1982; 248:2004-2011.
48. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
49. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
50. Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, et al., COLM Investigators. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: A randomized, controlled trial. J Hypertens 2014; 32:2054-2063.
51. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-Acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
52. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276:785-791.
53. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34:1129-1133.
54. Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR Study. J Hypertens 2004; 22:1613-1622.
55. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288:2421-2431.
56. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366:895-906.
57. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-Term trial. Circulation 2002; 106:2422-2427.
58. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290:2805-2816.
59. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.
60. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359:995-1003.
61. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with noninsulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-652.
62. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diab Care 1998; 21:597-603.
63. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27:181-191.
64. Baba S, J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001; 54:191-201.
65. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51:393-398.
66. Muramatsu T, Matsushita K, Yamashita K, Kondo T, Maeda K, Shintani S, et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension 2012; 59:580-586.
67. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363:2022-2031.
68. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289:2073-2082.
69. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-1961.
70. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
71. Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18:1889-1898.
72. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with nonnephrotic proteinuria. Lancet 1999; 354:359-364.
73. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349:1857-1863.
74. Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, et al. Angiotensin II receptor blocker-based vs. nonangiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30:1203-1212.
75. Hasford J, Mimran A, Simon WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 156:569-575.
76. Bourgault C, Sénécal M, Brisson M, Marentette MA, Gregiore J-P. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: A population-based study. J Hum Hypertens 2005; 19:607-613.
77. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2005; 24:1193-1200.
78. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-Treated patient: A population-based study in Italy. J Hypertens 2008; 26:819-824.
79. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31:1281-1357.